Atea Aims For Underserved HCV Niche With Combo Regimen
With high SVR rates and good safety/tolerability in Phase II, Atea hopes to take its antiviral combo into Phase III. It sees a need for hepatitis C regimens that boost therapeutic compliance.
With high SVR rates and good safety/tolerability in Phase II, Atea hopes to take its antiviral combo into Phase III. It sees a need for hepatitis C regimens that boost therapeutic compliance.